Clinical Trial Search

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: Overall Survival — 0; 0 Proportion of participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Complete Remission — 10 participants

Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…

Primary: Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) — 67.5; 76.2 percentage of participants

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Progression-free Survival at 2 Years — 76; 80 percentage of participants — p=0.11

Primary: Complete Response Rate at 20 Weeks — 45 percentage of participants

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants

Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg

Primary: Progression — 22; 1 participants — p=0.51

Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg

Primary: Progression-free Survival — 89 percentage of participants

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…

Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: 3 Years Event-free Survival — 51; 56; 126; 123 Participants

Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants

Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005